165 related articles for article (PubMed ID: 31028097)
21. Defining the role of antiandrogens in the treatment of prostate cancer.
McLeod DG; Kolvenbag GJ
Urology; 1996 Jan; 47(1A Suppl):85-9; discussion 90-6. PubMed ID: 8560682
[TBL] [Abstract][Full Text] [Related]
22. MDM2 Inhibition Sensitizes Prostate Cancer Cells to Androgen Ablation and Radiotherapy in a p53-Dependent Manner.
Feng FY; Zhang Y; Kothari V; Evans JR; Jackson WC; Chen W; Johnson SB; Luczak C; Wang S; Hamstra DA
Neoplasia; 2016 Apr; 18(4):213-22. PubMed ID: 27108384
[TBL] [Abstract][Full Text] [Related]
23. Marginal improvement in survival among patients diagnosed with metastatic prostate cancer in the second-line antiandrogen therapy era.
Kim IE; Jang TL; Kim S; Lee DY; Kim DD; Singer EA; Ghodoussipour S; Stein MN; Aron M; Dall'Era MA; Yi Kim I
Cancer Med; 2021 Nov; 10(22):7909-7920. PubMed ID: 34713977
[TBL] [Abstract][Full Text] [Related]
24. Ectopic expression of CC chemokine receptor 7 promotes prostate cancer cells metastasis via Notch1 signaling.
Du R; Tang G; Tang Z; Kuang Y
J Cell Biochem; 2019 Jun; 120(6):9639-9647. PubMed ID: 30548287
[TBL] [Abstract][Full Text] [Related]
25. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
Lavaud P; Gravis G; Foulon S; Joly F; Oudard S; Priou F; Latorzeff I; Mourey L; Soulié M; Delva R; Krakowski I; Laguerre B; Théodore C; Ferrero JM; Beuzeboc P; Habibian M; Rolland F; Deplanque G; Pouessel D; Zanetta S; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Tubiana-Mathieu N; Machiels JP; Kouri CE; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Culine S; Boher JM; Tergemina-Clain G; Legoupil C; Fizazi K
Eur Urol; 2018 May; 73(5):696-703. PubMed ID: 29074061
[TBL] [Abstract][Full Text] [Related]
26. Intra versus Inter Cross-resistance Determines Treatment Sequence between Taxane and AR-Targeting Therapies in Advanced Prostate Cancer.
Lombard AP; Liu L; Cucchiara V; Liu C; Armstrong CM; Zhao R; Yang JC; Lou W; Evans CP; Gao AC
Mol Cancer Ther; 2018 Oct; 17(10):2197-2205. PubMed ID: 29891490
[TBL] [Abstract][Full Text] [Related]
27. Patient-derived Hormone-naive Prostate Cancer Xenograft Models Reveal Growth Factor Receptor Bound Protein 10 as an Androgen Receptor-repressed Gene Driving the Development of Castration-resistant Prostate Cancer.
Hao J; Ci X; Xue H; Wu R; Dong X; Choi SYC; He H; Wang Y; Zhang F; Qu S; Zhang F; Haegert AM; Gout PW; Zoubeidi A; Collins C; Gleave ME; Lin D; Wang Y
Eur Urol; 2018 Jun; 73(6):949-960. PubMed ID: 29544736
[TBL] [Abstract][Full Text] [Related]
28. Survivin mediates resistance to antiandrogen therapy in prostate cancer.
Zhang M; Latham DE; Delaney MA; Chakravarti A
Oncogene; 2005 Apr; 24(15):2474-82. PubMed ID: 15735703
[TBL] [Abstract][Full Text] [Related]
29. Tumor-associated macrophages in direct contact with prostate cancer cells promote malignant proliferation and metastasis through NOTCH1 pathway.
Shi F; Sun MH; Zhou Z; Wu L; Zhu Z; Xia SJ; Han BM; Zhao YY; Jing YF; Cui D
Int J Biol Sci; 2022; 18(16):5994-6007. PubMed ID: 36439868
[No Abstract] [Full Text] [Related]
30. GnRH agonists and the rapidly increasing use of combined androgen blockade in prostate cancer.
Labrie F
Endocr Relat Cancer; 2014 Aug; 21(4):R301-17. PubMed ID: 24825748
[TBL] [Abstract][Full Text] [Related]
31. Synergistic effect of a novel antiandrogen, VN/124-1, and signal transduction inhibitors in prostate cancer progression to hormone independence in vitro.
Schayowitz A; Sabnis G; Njar VC; Brodie AM
Mol Cancer Ther; 2008 Jan; 7(1):121-32. PubMed ID: 18202015
[TBL] [Abstract][Full Text] [Related]
32. Cell death under epithelial-mesenchymal transition control in prostate cancer therapeutic response.
Begemann D; Anastos H; Kyprianou N
Int J Urol; 2018 Apr; 25(4):318-326. PubMed ID: 29345000
[TBL] [Abstract][Full Text] [Related]
33. Emerging therapies in metastatic castration-sensitive and castration-resistant prostate cancer.
MacVicar GR; Hussain MH
Curr Opin Oncol; 2013 May; 25(3):252-60. PubMed ID: 23511665
[TBL] [Abstract][Full Text] [Related]
34. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
Suzuki H; Okihara K; Miyake H; Fujisawa M; Miyoshi S; Matsumoto T; Fujii M; Takihana Y; Usui T; Matsuda T; Ozono S; Kumon H; Ichikawa T; Miki T;
J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218
[TBL] [Abstract][Full Text] [Related]
35. Integrated Therapeutic Targeting of the Prostate Tumor Microenvironment.
Livas L; Hasani S; Kyprianou N
Adv Exp Med Biol; 2020; 1296():183-198. PubMed ID: 34185293
[TBL] [Abstract][Full Text] [Related]
36. Androgen receptor: role and novel therapeutic prospects in prostate cancer.
Taplin ME
Expert Rev Anticancer Ther; 2008 Sep; 8(9):1495-508. PubMed ID: 18759700
[TBL] [Abstract][Full Text] [Related]
37. Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance.
Ku SY; Rosario S; Wang Y; Mu P; Seshadri M; Goodrich ZW; Goodrich MM; Labbé DP; Gomez EC; Wang J; Long HW; Xu B; Brown M; Loda M; Sawyers CL; Ellis L; Goodrich DW
Science; 2017 Jan; 355(6320):78-83. PubMed ID: 28059767
[TBL] [Abstract][Full Text] [Related]
38. Cellular identity crisis: Antiandrogen resistance by lineage plasticity.
Tuerff D; Sissung T; Figg WD
Cancer Biol Ther; 2017 Nov; 18(11):841-842. PubMed ID: 28475401
[TBL] [Abstract][Full Text] [Related]
39. Tumor Microenvironment-Derived NRG1 Promotes Antiandrogen Resistance in Prostate Cancer.
Zhang Z; Karthaus WR; Lee YS; Gao VR; Wu C; Russo JW; Liu M; Mota JM; Abida W; Linton E; Lee E; Barnes SD; Chen HA; Mao N; Wongvipat J; Choi D; Chen X; Zhao H; Manova-Todorova K; de Stanchina E; Taplin ME; Balk SP; Rathkopf DE; Gopalan A; Carver BS; Mu P; Jiang X; Watson PA; Sawyers CL
Cancer Cell; 2020 Aug; 38(2):279-296.e9. PubMed ID: 32679108
[TBL] [Abstract][Full Text] [Related]
40. Antiandrogen gold nanoparticles dual-target and overcome treatment resistance in hormone-insensitive prostate cancer cells.
Dreaden EC; Gryder BE; Austin LA; Tene Defo BA; Hayden SC; Pi M; Quarles LD; Oyelere AK; El-Sayed MA
Bioconjug Chem; 2012 Aug; 23(8):1507-12. PubMed ID: 22768914
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
